Water Immersion in Right-Sided Heart Failure: A Pilot Study

This study has been completed.
Information provided by (Responsible Party):
Steve Gottlieb, University of Maryland
ClinicalTrials.gov Identifier:
First received: April 1, 2008
Last updated: October 27, 2011
Last verified: October 2011
This is an unblinded pilot study comparing (against a randomized control day without water immersion) the diuretic and natriuretic effects of water immersion in patients with right heart failure.

Condition Intervention Phase
Right Sided Cardiac Failure
Procedure: Water immersion
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Water Immersion in Right-Sided Heart Failure: A Pilot Study

Resource links provided by NLM:

Further study details as provided by University of Maryland:

Primary Outcome Measures:
  • Diuresis [ Time Frame: 4 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Neurohormonal activation [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
  • Natriuresis [ Time Frame: 4 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 13
Study Start Date: December 2007
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Patients will have water immersion on first day and sitting in a tub without water on the second day.
Procedure: Water immersion
Subjects will sit in tub for four hours.
Patients will sit in a tub without water on the first day and have water immersion on the second day.
Procedure: Water immersion
Subjects will sit in tub for four hours.

Detailed Description:
Patients will be immersed in a tub for 3 hours (on one day) and neurohormones will be obtained before and after immersion. Urine will be collected for quantification and evaluation of sodium concentration.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have right sided failure secondary to right ventricular dysfunction, pulmonary hypertension, or tricuspid regurgitation
  • Age greater than 18 years of age
  • Right heart catheterization within the last year to rule out left-sided failure.
  • Evidence of fluid overload as indicated by 2 or more of the following: 1.) 2+ or more pitting edema of the lower extremities, 2.) scrotal or penile edema, 3.) JVP greater than or equal to 10 cm, 4.) abdominal ascites

Exclusion Criteria:

  • Pulmonary capillary wedge pressure above 16 mmHg or history of elevated left ventricular filling pressures.
  • Serum creatinine > 2.0
  • Current use of an angiotensin I converting enzyme inhibitor or angiotensin receptor blocker will preclude participation in the RAS neurohormone portion of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00654264

United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
University of Maryland
Principal Investigator: Stephen Gottlieb, MD University of Maryland
  More Information

No publications provided

Responsible Party: Steve Gottlieb, Professor, University of Maryland
ClinicalTrials.gov Identifier: NCT00654264     History of Changes
Other Study ID Numbers: H-29283 
Study First Received: April 1, 2008
Last Updated: October 27, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities
Heart Defects, Congenital
Heart Diseases
Situs Inversus

ClinicalTrials.gov processed this record on February 04, 2016